The ICR142 NGS validation series: a resource for orthogonal assessment of NGS analysis

Introduction

Next-generation sequencing (NGS) approaches have greatly enhanced our ability to detect genetic variation. Over the past decade NGS hardware, software, throughput, data quality and analytical tools have evolved dramatically. Thorough evaluation of each new laboratory and analytical development is challenging but necessary to fully understand how pipeline modification can impact results. To fully assess performance, NGS analysis tools should ideally be run on samples with pre-determined positive and negative sites assessed through orthogonal experimentation such as Sanger sequencing.

Over the past five years, we have generated extensive data on thousands of samples using different NGS instruments, sequencing chemistry, gene panels, exome captures and variant calling tools. Fortuitously, during this process we have generated orthogonal validation data using Sanger sequencing for a core set of 142 samples that were included in the majority of our experiments. We now formally use these samples, which we call the ICR142 NGS validation series, to evaluate NGS variant calling performance after any change to experimental or analytical protocols. This series has proved an extremely useful resource for our assessment of NGS analysis in both the research and clinical settings. We believe that it may also have utility for others, and hence are making it available here.

Materials and methods

We used lymphocyte DNA from 142 unrelated individuals. All individuals were recruited to the BOCS study and have given informed consent for their DNA to be used for genetic research. The study is approved by the London Multicentre Research Ethics Committee (MREC/01/2/18)

Over the last five years we have generated data from the ICR142 validation series using different exome captures which we have analysed with multiple aligner/caller combinations^1–6. To date we have generated Sanger sequence data for 730 sites amongst the 142 individuals. These sites include variants called by only one aligner and caller combination, increasing the representation of sites which can discriminate performance between methods.

To generate the Sanger sequence data, we performed PCR reactions using the Qiagen Multiplex PCR kit, and bidirectional sequencing of resulting amplicons using the BigDye terminator cycle sequencing kit and an ABI3730 automated sequencer (ABI PerkinElmer). All sequencing traces were analysed with both automated software (Mutation Surveyor version 3.10, SoftGenetics) and visual inspection.

We considered a site negative for a base substitution if the specific base substitution was not present, resulting in 46 negative base substitution sites. We considered a site negative for an indel if no indel, of any kind, was detected in the sequencing trace, resulting in 275 negative indel sites. We annotated confirmed variants with the HGVS-compliant CSN standard using CAVA (version 1.1.0) according to the transcripts designated in Supplementary table 1⁷. There were 123 confirmed base substitution variants and 286 confirmed indel variants (Figure 1, Supplementary table 1).

Figure 1. Description of variant sites evaluated by Sanger sequencing in the ICR142 NGS validation series.

We have also generated high-quality exome sequencing data for the ICR142 NGS validation series. We prepared DNA libraries from 1.5 µg genomic DNA using the Illumina TruSeq sample preparation kit. DNA was fragmented using Covaris technology and the libraries were prepared without gel size selection. We performed target enrichment in pools of six libraries (500 ng each) using the Illumina TruSeq Exome Enrichment kit. The captured DNA libraries were PCR amplified using the supplied paired-end PCR primers. Sequencing was performed with an Illumina HiSeq2000 (SBS Kit v3, one pool per lane) generating 2×101 bp reads. CASAVA v1.8.1 (Illumina) was used to demultiplex and create FASTQ files per sample from the raw base call files.

All of the 730 sites had at least 15× coverage in the exome data, defined as at least 15 reads of good mapping quality (mapping score ≥20). Because these sites are well covered, we can readily assess the variant calling performance of any software tool by applying the pipeline to the exome sequencing data and comparing the variant calls with the Sanger sequencing dataset.

Data availability

We have deposited the FASTQ files for all 142 individuals in the European Genome-phenome archive (EGA). The accession number is EGAS00001001332. Details of how to request access to the data are available at: www.icr.ac.uk/icr142.

Researchers and authors that use the ICR142 NGS validation series should reference this paper and should include the following acknowledgement: "This study makes use of the ICR142 NGS validation series data generated by Professor Nazneen Rahman’s team at The Institute of Cancer Research, London”.